Plain-English translation of NCT06119581 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Carcinoma, Non-Small-Cell Lung research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called olomorasib () combined with , an immunotherapy drug that helps your immune system fight cancer. Some participants will also receive chemotherapy along with these medications. The trial is looking at whether this combination can help people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C.
Currently, treatment options for people with this type of advanced lung cancer are limited. Researchers believe that combining this new medication with existing immunotherapy may be more effective at slowing or stopping cancer growth than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication plus , or a placebo plus (and possibly chemotherapy, depending on which part of the study you join). You will take the medication orally or receive infusions intravenously in 21-day treatment cycles. You will continue receiving treatment until your cancer progresses, you experience unacceptable side effects, or your doctor decides to stop treatment. Throughout the trial, you will have regular visits for blood tests, scans, and check-ups to monitor how well the treatment is working and any side effects.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States